Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic neoplasms (MDS) are clonal stem cell disorders marked by dysplasia, ineffective hematopoiesis, and risk of acute myeloid leukemia (AML).
• Understanding and classification of MDS have evolved significantly, with recent updates from the World Health Organization (WHO5) and International Consensus Classification (ICC 2022).
• Prognostication and treatment strategies are increasingly influenced by cytogenetic and molecular data, including specific genetic abnormalities.

Purpose of the Study:

• To review the current understanding of myelodysplastic neoplasms, focusing on evolving classifications and treatment paradigms.
• To highlight the impact of genetic abnormalities on MDS phenotype and patient outcomes.
• To discuss current treatment approaches for lower-risk and higher-risk MDS and the potential of novel therapies.

Main Methods:

• Literature review of recent advancements in MDS classification, prognostication, and treatment.
• Analysis of the role of specific genetic mutations (e.g., del(5q), TP53, SF3B1) in MDS.
• Discussion of therapeutic strategies, including symptom management, disease-directed therapy, bone marrow transplantation, and emerging novel treatments.

Main Results:

• MDS classification systems (WHO5, ICC 2022) now integrate cytogenetic and molecular data for improved accuracy.
• Specific genetic abnormalities are strongly associated with distinct MDS phenotypes and clinical outcomes.
• While novel targeted therapies are under development, few have gained recent approval, underscoring the need for continued research.

Conclusions:

• Genetic profiling is crucial for accurate MDS prognostication and personalized treatment strategies.
• Current treatments for lower-risk MDS focus on symptom management, while higher-risk disease may require allogeneic bone marrow transplant.
• Ongoing research into molecular and cellular pathways holds promise for developing more effective, tailored therapies to improve outcomes for MDS patients.